Palvella Therapeutics, Inc.PVLA

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · palvellatx.com

Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its pipeline is based on the patented QTORIN platform, led by QTORIN rapamycin, in development for microcystic lymphatic malformations, cutaneous venous malformations and clinically significant angiokeratomas, plus QTORIN pitavastatin for disseminated superficial actinic porokeratosis.

Key ratios

ROA

-32.7%2025

2024 -18.4%2023 -61.6%

ROE

-46.6%TTM

2025 -92.1%2024 -59.4%

Recent news

Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer 2026-09-09 · GlobeNewswire Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations 2026-08-31 · GlobeNewswire

Track PVLA in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer